February 11, 2015 08:00 AM Eastern Standard Time
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the appointment of Sylvia R. Wheeler to the position of senior vice president, Corporate Affairs and Investor Relations. Ms. Wheeler, a veteran biopharmaceutical executive, joins Aduro with over 20 years of experience driving communications strategies and initiatives. In her new role, Ms. Wheeler will be a member of the executive leadership team and will report to Stephen T. Isaacs, chairman, president and chief executive officer of Aduro.
“Sylvia has served as a communications advisor to Aduro for many years prior to joining us now as a member of our executive leadership team,” said Mr. Isaacs. “We are pleased to have her on board as we enter a transformative stage at the company with our immuno-oncology technology platforms advancing in multiple clinical trials to treat a variety of cancers, including pancreatic, lung, prostate and mesothelioma as well as a number of other programs in preclinical development. We look forward to Sylvia’s leadership as we seek to build value, expand our activities and raise visibility with our key audiences and stakeholders.”
Ms. Wheeler was most recently vice president, Investor Relations and Corporate Affairs at Relypsa, a biopharmaceutical company, where she led the company’s corporate and product communications and was responsible for reputation management. Prior to joining Relypsa, she served as vice president, Corporate Communications for Hyperion Therapeutics and before that she was vice president, Investor Relations for Affymax, Inc. Ms. Wheeler also served in similar functions at Depomed, Inc., Cerus Corporation and Coulter Pharmaceuticals, Inc., all healthcare-focused companies, and at Russell Welsh, a communications agency focused exclusively on the bioscience industry. Ms. Wheeler earned her M.B.A from the University of San Francisco and a B.A. in Biology from San Francisco State University.
Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company focused on the development of its live, attenuated, double-deleted (LADD) Listeria monocytogenes and cyclic dinucleotide (CDN) technology platforms to initiate powerful innate immune responses and drive targeted, durable adaptive immune responses against cancer. Aduro has received Breakthrough Therapy designation from the FDA for its lead immuno-oncology regimen, CRS-207 and GVAX Pancreas, in pancreatic cancer. The company is evaluating CRS-207 and GVAX Pancreas in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD product candidates in mesothelioma and glioblastoma. The company is also developing clinical candidates using synthetic small molecule CDNs that are designed to activate the intracellular STING receptor. For more information, please visit www.aduro.com.
Aduro Biotech, Inc.
Sylvia Wheeler, 510-809-9264
SVP, Corporate Affairs
Angela Bitting, 925-202-6211